

Medicare Advantage Drugs/Biologics Part B Prior Authorization Form



Part B Step Therapy – Stelara IV, Imuliosa IV, Otolifi IV, Pyzchiva IV, Starjemza IV, Steqeyma IV, Ustekinumab (unbranded Stelara) IV, Ustekinumab-ttwe IV, Wezlana IV, Yesintek IV

This form applies to all HealthSpring Medicare Advantage markets. It does not apply to Medicaid only and Medicare-Medicaid Plans (MMP). Please fax to **877-730-3858** | Phone: **888-454-0013**

To ensure your request is processed in a timely manner, please submit all pertinent clinical information.

<input type="checkbox"/> Expedited – defined as danger to a member's health if not provided within 24 hours	
Member name	Member date of birth
Requesting provider	Member ID
Contact person	Date of service
Address	
NPI	Phone
	Fax

If referring to a servicing provider, the information below must be submitted.	
Servicing provider	Phone
Contact person	Fax
Address	NPI
<input type="checkbox"/> Check here if servicing provider is out of network. Please explain.	
Who will supply the medication?	Please select place of service by checking only one of the boxes
<input type="checkbox"/> Provider office	<input type="checkbox"/> Provider office
<input type="checkbox"/> Outpatient hospital/clinic	<input type="checkbox"/> Outpatient hospital/clinic
<input type="checkbox"/> Pharmacy not located within the servicing facility	<input type="checkbox"/> Other. Please specify _____
Diagnosis codes	Diagnosis

Please attach all required documentation: recent clinical notes, copy of the prescription or provider order, and relevant diagnostic lab results.				
HCPCS codes	Drug (if applicable)	Dose (if applicable)	Frequency	Duration
Is this a new start or a continuation of therapy within the past 365 days?				
Has the member had an intolerance or an inadequate response to Step 1 alternative Selarsdi IV, Ustekinumab aekn IV?*				
If the member is unable to try Step 1 alternative Selarsdi IV, Ustekinumab aekn IV, please provide the reason(s) an exception should be made to the step therapy requirement.				

*HealthSpring requires prior authorization for Step 1 alternative – Selarsdi IV, Ustekinumab aekn IV.